Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Company’s mission of health equity.

In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his “vision to make healthcare more affordable and accessible” and the impact that Tevogen Bio has had on the world.

Tevogen’s business model is designed to withstand current market pressures through a lean, capital-efficient structure. By fully owning its core intellectual property and avoiding costly licensing overhead, the Company is uniquely positioned to develop off-the-shelf, genetically unmodified CD8+ T cell therapies that aim to reduce manufacturing complexity and cost.

“We are humbled and honored by this recognition,” said Dr. Saadi. “As Yale has highlighted, affordability and accessibility are not just aspirational goals for Tevogen, they are the foundation of how we operate. We’ve deliberately avoided the billion-dollar burn norm of our industry, reaching this stage well under typical industry spend in five years with equity largely preserved and a lean monthly cash run rate. We believe that true innovation not only delivers better patient outcomes but also achieves commercial success at lower cost. With access to capital and a strong operational platform, we remain steadfast in our mission to make transformative therapies broadly available.”

Forward-Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

A photo accompanying this announcement is available at: